Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $4.22 Analyst target: $34.89 Upside: 726.78%
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapies that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. The company is headquartered in Norwood, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.